obesity drug news today glp-1 october 21 2025 New Daily Weight Loss Pill Aims to Take on Ozempic Obesity GLP-1 Market

Conflict of interest TMMT is a shareholder and consultant for Zihipp Ltd., which is developing gut hormone analogues for treatment of metabolic disease

When you use them (instead of your Medicare plan) to buy drugs, it doesnt count toward your Medicare deductible or out-of-pocket maximum

The market dynamics are further influenced by the introduction of oral formulations

Notably, the Ozempic group showed an HR of 1.72 (95% CI 1.671.76), and the Wegovy group presented a significantly higher HR of 2.14 (95% CI 2.052.24)

Its ability to promote weight loss can also alleviate obesity-related stress on the kidneys, improving overall kidney function

As early as the mid-20th century, studies of commercial diet programs showed that while short-term weight loss was common, regaining weight long term was the norm